Close Menu

Flagship Biosciences

The companies announced a strategic venture to provide comprehensive biomarker profiling to empower clinical trials in the immuno-oncology space.

Flagship Bio is using ACD's RNAscope and customizing and optimizing the technology for use in CLIA clinical trials with "several large pharmaceutical clients."

NEW YORK (GenomeWeb) – Danaher's Leica Biosystems will use Flagship Biosciences' custom algorithms to develop companion diagnostics on the Aperio ePathology imaging platform, Flagship said today.
Financial and other terms of the deal were not disclosed.

Flagship Biosciences will use Affymetrix Quantigene ViewRNA assays as part of a new tissue-based RNA in situ hybridization analysis service.

NEW YORK (GenomeWeb News) – Companion diagnostics and biomarker development company Flagship Biosciences announced late on Monday its purchase of immunohistochemistry and immunofluorescence firm IHCtech for an undisclosed amount.

The deal combines TGen's molecular analysis tools with Flagship's expertise in high-throughput immunohistochemistry to support preclinical drug development and human clinical trials.

The deal combines Expression Pathology's mass spec-based assays for FFPE tissue with Flagship's pathology expertise, allowing the partners to identify tissue features or sub-anatomic organelles of research interest and then extract and prep them for proteomic analysis.

The partnership will enable tissue translational biomarker development, validation, and application to support new drug development, according to Flagship Biosciences.

Epigenetics company PrognosDx and digital pathology firm Flagship will offer laboratory-based testing services initially to therapeutic oncology programs at pharmaceutical firms.

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.